Clinical Trial Update: The Safety, Tolerability and Pharmacokinetic Study of RAY1225 [Phase 1]

View source ↗

Summary

Phase 1 safety, tolerability and pharmacokinetic study of RAY1225 completed in obese and healthy participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• RAY1225

Snippet

Sponsor: Guangdong Raynovent Biotech Co., Ltd | Conditions: Obese, Healthy | Phase 1 | Status: COMPLETED